- News & Features
The FDA findings are based upon a Dec. 2016 study of more than 24,000 osteoarthritis and rheumatoid arthritis patients.
Researchers found that younger patients, as well as those whose disease was more active, were likelier to stop taking methotrexate due to ineffectiveness.
Asking your doctor is among the best ways to find out about new treatments and clinical trials.
The introduction of biologic disease-modifying anti-rheumatic drugs are associated with a decrease in total knee replacements among RA patients.
Rheumatoid arthritis patients who take opioids or antidepressants are likelier to fracture their bones, according to research presented at the 2017 American College of Rheumatology annual meeting in San Diego.
“The results of this preliminary study may help rheumatologists to differentiate RA patients who would successfully down-titrate biologics”
Treat-to-target, evidence-based guidelines recommend that rheumatoid arthritis patients be monitored regularly for disease activity and that therapy is adjusted —...
“This is particularly notable, since the cohort consisted of the harder-to-treat patients, meaning those with long-standing disease with prior use of other biologic agents,” Dr. Harrold says.
Boehringer Ingelheim announced it had enrolled the first patient in a study intended to demonstrate that a biosimilar is interchangeable with Humira (adalimumab) for treating patients with moderate-to-severe chronic plaque psoriasis.
In tests, seven out of 10 patients who took the newly-approved drug experienced improvements in their skin of at least 90 percent, and 80 percent saw cleared or almost cleared skin.
New study suggests that it might be worthwhile to monitor & address pain/fatigue in addition to and independently of disease activity in early RA.